Kenvue CFO Sold Shares After Its Strongest Earnings Beat
Kenvue reported a 23.1% EPS beat in May 2026, the fourth consecutive quarterly outperformance, then CFO Heather Howlett sold 3,700 shares at $18.11 in June. The stock has since risen to $19.55, within
Kenvue CFO Sold Shares After Its Strongest Earnings Beat
NEW YORK, August 5 —
Kenvue Inc. (KVUE) delivered its strongest quarterly earnings beat in four reported quarters in May 2026; then its CFO sold shares. Heather Howlett's open-market disposal at $18.11 in June now looks like a call: the stock has risen to $19.55, less than 1.5% below the $19.83 analyst consensus, suggesting the beat streak is already priced in.
- EPS of $0.32 beat the consensus by 23.1%; fourth consecutive quarterly beat, per the May 7, 2026 8-K.
- CFO Heather Howlett sold 3,700 shares at $18.11 on June 10, the only open-market insider disposal in the 90-day window.
- Net debt of ~$7.72B runs roughly four times trailing free cash flow of $1.858B; analyst consensus price target is $19.83.
The Streak Is Not Noise
Kenvue, which sells Tylenol and Motrin through its Self Care segment, Neutrogena and Aveeno through Skin Health and Beauty, and Listerine and Band-Aid through Essential Health, has outrun analyst EPS estimates in each of its last four quarters, with positive surprise magnitudes of 2.1%, 7.6%, 22.5%, and 23.1% in succession. The acceleration is the signal: a single modest beat can be noise; two consecutive beats above 20% indicates a systematic gap between guidance and delivery. Trailing twelve-month revenue of $15.29 billion grew 4.5% year-over-year, and gross margin of 58.6% gives the business real operating leverage.
The CFO's Timing Is a Data Point
Heather Howlett, Kenvue's CFO and chief accounting officer, sold 3,700 shares at $18.11 on June 10, 2026, roughly five weeks after the company disclosed the 23.1% EPS beat in its May 7, 2026 8-K filing. Net insider activity over 90 days shows $0 in open-market purchases; her disposal is the only arms-length sale, all other transactions being option exercises or tax-withholding events. At $19.55 on 15.7x forward earnings, KVUE now trades within 1.4% of the $19.83 analyst consensus, a spread so thin it offers almost no buffer for disappointment.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| KVUE | $37.5B | 15.7x | -12.2% |
| KDP | $42.3B | 12.3x | -7.2% |
| AMCR | $21.8B | 11.0x | -1.9% |
| GEHC | $32.0B | 13.0x | -1.4% |
| HLN | $43.1B | 15.9x | +5.5% |
| CAVA | $7.4B | 84.3x | -26.4% |
The Multiple Has Caught Up With the Momentum
The neutral position rests on explicit arithmetic: Kenvue's net debt of approximately $7.72 billion, against trailing free cash flow of $1.86 billion, runs to roughly four times coverage, a leverage profile that caps the upside multiple regardless of beat frequency. The thesis shifts if a fifth consecutive beat arrives alongside revenue growth accelerating beyond 4.5%, or if debt paydown narrows the gap, a sensitivity the DCF calculator makes concrete. Howlett's June disposal does not prove the stock is capped; it proves the CFO, with first-hand access to the ledger, found insufficient margin to hold. Run the free Kenvue Inc. deep-dive →
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Did Kenvue beat earnings estimates in May 2026?
Yes. Kenvue reported EPS of $0.32 against a $0.2601 consensus, a 23.1% positive surprise, disclosed in the May 7, 2026 8-K filing. This was the fourth consecutive quarterly beat, with successive surprise magnitudes of 2.1%, 7.6%, 22.5%, and 23.1%.
Why did Kenvue's CFO sell shares in June 2026?
Heather Howlett, Kenvue's CFO and chief accounting officer, sold 3,700 shares at $18.11 on June 10, 2026, roughly five weeks after the 23.1% EPS beat was disclosed. She was the only insider to make an open-market disposal in the 90-day window; all other transactions were option exercises or tax-withholding events.
Is Kenvue stock near its analyst price target?
At $19.55 on 15.7x forward earnings, Kenvue trades within 1.4% of the $19.83 analyst consensus price target. That spread is thin enough to offer almost no buffer for disappointment, according to the article's valuation analysis.
What is Kenvue's debt load relative to cash flow?
Kenvue carries net debt of approximately $7.72 billion against trailing free cash flow of $1.86 billion, a coverage ratio of roughly four times. The article argues this leverage profile caps the upside multiple regardless of how often the company beats estimates.
What brands does Kenvue sell?
Kenvue sells Tylenol and Motrin through its Self Care segment, Neutrogena and Aveeno through Skin Health and Beauty, and Listerine and Band-Aid through Essential Health. Trailing twelve-month revenue of $15.29 billion grew 4.5% year-over-year on a gross margin of 58.6%.
Kenvue CFO Heather Howlett sold 3,700 shares on the open market at $18.11 in June 2026 — roughly one month after the company posted its strongest earnings beat in four quarters. The stock has since climbed to $19.55, above her exit price but barely below the $19.83 analyst consensus, raising the question of whether the chief financial officer correctly identified a valuation ceiling the market is now approaching.